allogeneic t cell progenitors, cultured ex-vivo
Cell therapyexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Sep 30, 2021 (NCT04959903)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- T-lymphocytesSupplementation
T-lymphocytes supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05768035 | Phase 1/Phase 2 (Phase 2) | Jun 6, 2023 | Smart Immune SAS |
| NCT04959903 | Phase 1/Phase 2 (Phase 2) | Sep 30, 2021 | Memorial Sloan-Kettering Cancer Center, Smart Immune SAS |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Smart Immune SAS | For profit | 2 | 2 | 1 | 2021 |
| Memorial Sloan-Kettering Cancer Center | Academic/Hospital | 1 | 0 | 1 | 2021 |
2 organizations
Page 1 / 1